ITRASPORAX 50 SB CAP is a broad-spectrum antifungal formulation containing Itraconazole 50 mg, a potent triazole derivative with high efficacy against dermatophytes, yeasts, and systemic fungi. This sustained-release (SB) form is developed to deliver a gradual release of Itraconazole, ensuring longer-lasting therapeutic activity, improved bioavailability, and better patient adherence.

Itraconazole acts by inhibiting the fungal cytochrome P450-dependent enzyme lanosterol 14-alpha-demethylase, a critical enzyme in the synthesis of ergosterol, an essential component of fungal cell membranes. By disrupting this pathway, Itraconazole halts fungal cell growth and replication.

Indications and Therapeutic Uses

ITRASPORAX 50 SB CAP is recommended in the treatment of:

Dermatophytosis (Tinea corporis, Tinea cruris, Tinea pedis)

Onychomycosis (fungal nail infections)

Pityriasis versicolor

Oral and esophageal candidiasis

Vaginal candidiasis

Aspergillosis (non-invasive)

Histoplasmosis & Blastomycosis

Sporotrichosis and systemic mycoses

Fungal infections resistant to fluconazole

Key Benefits of ITRASPORAX 50 SB CAP

Sustained release ensures prolonged antifungal effect

Effective in both superficial and deep/systemic fungal infections

Superior to other azoles in lipophilic tissue penetration

Lower dosage frequency enhances patient compliance

Bioavailability improved when taken with food

Suitable for long-term antifungal therapy

Dosage and Administration

Usual adult dosage: 50–200 mg/day, depending on indication

Fungal skin infections: 50–100 mg once or twice daily for 2–4 weeks

Onychomycosis: Pulse therapy 200 mg twice daily for 1 week/month over 3–4 months

Should be taken with food to enhance absorption

Dosage adjustments required in hepatic impairment

Note: Always follow physician's recommendations for duration and dosage.